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The purpose of this study is to compare histological and clinical variables of 
individuals with Lynch Syndrome associated Endometrial Carcinoma with a cohort with 
sporadic Endometrial Carcinomas derived from the general population with sporadic 
Endometrial Carcinomas. The patients in the Lynch Syndrome cohort were genetically 
confirmed carriers of MSH2 mismatch repair gene mutations all with previously 
diagnosed Endometrial Carcinoma.  
 
Methods  
Clinical data was abstracted retrospectively from the medical charts of 46 women 
with endometrial caner who had a known MSH2 mismatch repair mutation confirmed 
through genetic sequencing. Clinical variables abstracted from the medical files of these 
patients included (1) Age at diagnosis (2) International Federation of Gynecology and 
Obstetrics (FIGO) Stage (3) International Federation of Gynecology and Obstetrics Grade 
and (4) Cell type of endometrial carcinoma. The characteristics of the MSH2 carriers 
were subsequently compared to the clinically relevant variables of sporadic endometrial 
cancers that were retrieved from the Newfoundland and Labrador Cancer Care Registry 
(NLCCR) diagnosed between 2000 and 2010. The Newfoundland and Labrador Cancer 
Care Registry is a provincial cancer care program and database operated by Eastern 
Health that combines 5 core cancer programs and registries. The NLCCR includes the 
provinces Colon, Breast and Cervical screening programs and the provincial tumour and 
systemic therapy surveillance programs. 
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Results  
The mean age at diagnosis of Endometrial Cancer (EC) in the MSH2 Lynch 
syndrome mutation carriers was 46.3 years vs. 60.9 years in the sporadic cohort 
(p=<0.001). The Lynch Syndrome ECs were diagnosed more frequently prior to 55 years 
of age (p=<0.001). Comparing local and advanced stages of disease, the Lynch Syndrome 
cohort had more advanced disease at diagnosis (p=0.047).  The prevalence of papillary 
serous cell type carcinomas in the Lynch Syndrome (23.7%) cohort was statistically more 
frequent than in the sporadic cohort (3.6%)  (p=< 0.001). Clear cell carcinomas were 
observed more frequently in Lynch Syndrome related EC (7.9%) compared to the 
sporadic cohort (0.8%) (p=<0.001). The prevalence of grade 3 tumours in the Lynch 
Syndrome related EC cohort was higher compared to the sporadic cohort; 32.4% and 
11.9% respectively (p=0.001). Merger of low-grade (1/2) tumours compared to high-
grade (3) tumours observed the Lynch Syndrome cohort to present with higher-grade 
tumours. In the Lynch Syndrome cohort 69.6% had endometrial carcinoma as a sentinel 
cancer. Survival after diagnosis of EC was similar in each cohort (p=0.068). Logistic 
regression models indicated that a diagnosis of EC prior to age 55 and a histological 
diagnosis of papillary serous/clear cell carcinoma to were independently associated with 
LS (p=<0.001 and p=<0.001 respectively). Multivariate analysis demonstrated that grade, 







This is a preliminary study focusing on the clinical features present in Lynch Syndrome 
related endometrial carcinomas in women carrying MSH2 mismatch repair mutations. 
This study serves as a pilot study for a larger, population-based study of the genetics and 
epidemiology of endometrial carcinomas in Newfoundland and Labrador. We have 
concluded that Lynch Syndrome associated endometrial cancers are diagnosed at a 
younger age than the endometrial cancers in the general population, and that prevalence 
of cell types with unfavorable prognosis was higher in Lynch Syndrome related 
endometrial carcinomas. The stage of cancer in the Lynch syndrome related endometrial 
carcinoma cohort at diagnosis was more advanced, and was associated with a higher 
histological grade. Multivariate analysis found these characteristics to be predictive of 
LS.  Lynch Syndrome related EC patients demonstrated no difference in survival 
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Chapter 1: Introduction 
 
In a 1966 paper published by Dr. Henry T. Lynch described two large kindreds 
with familial cancer syndrome from the Midwestern United States; Families “M” and 
“N”. These two families were remarkably similar to a large pedigree (Family “G”) 
published by Warthin et al (1913). These three families in conglomeration with 
enumerable similar families over the decades led to the description of the classic 
phenotype and subsequent genotype of Lynch Syndrome still being described today. 
 
The term Lynch Syndrome has often been confused with and misused as being 
synonymous with Hereditary Non-Polyposis Colorectal Cancer (HNPCC) throughout the 
literature. This is most likely due to the initial recognition of the familial cancers that 
were predominantly colorectal adenocarcinomas, in turn leading to genetic discovery of 
LS. HNPCC is a clinical diagnosis of an individual or family that satisfies the Amsterdam 
or the revised Amsterdam II criteria, conversely LS is defined by the presence of a 
germline mutation in a DNA mismatch repair (DNA-MMR) gene; these genes include 
MSH2, MSH6, MLH1, and PMS2. This is incredibly important for maintaining clarity 
within the research field and in order to make a clear comparison between studies that 
tend to use these terms interchangeably. Not differentiating LS from HNPCC leads to 
ambiguity in research findings and difficulty when it comes to applying research to 
patient management recommendations including risk stratification (Kravochuck,	2014). 
Moving forward, it is of the upmost importance that researchers make a clear distinction 
between the two terms in order to further develop the understanding of the genotype-
phenotype relationship in LS as well as increasing the comparability of studies and their 
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cohorts. Moving forward in this study the term LS will be used to describe probands with 
a confirmed DNA-MMR mutation (Kravochuck, 2014).  
 
Lynch Syndrome is defined in terms of the presence of a germline mutation in 
DNA mismatch repair (MMR) genes including mutations at the MSH2, MSH6, MLH1, or 
PMS2 loci. LS is characterized by vertical progression through pedigrees demonstrating 
autosomal dominant inheritance pattern as well as early age of diagnosis of ECs and 
colorectal cancer. Many individuals affected with LS are observed to have an increased 
prevalence of synchronous and metachronous neoplasms. Additionally, this hereditary 
cancer syndrome has been associated with a spectrum of neoplasms besides colorectal 
and endometrial cancers that include cancers of the genitourinary tract, ovaries, biliary 
tract, pancreas, and the brain (Stuckless, 2007). LS demonstrates incomplete penetrance 
in that not all individuals carrying a MMR gene mutation will present with the disease 
phenotype; penetrance is influenced by the mutation possessed by probands. The lifetime 
risk of developing an EC in individuals with LS is estimated to be 30-70% (Stuckless 
2007); certain studies demonstrate the risk of EC is equal to or exceeds the risk of 
compared to colorectal cancer.  
 
Current literature describing the genotype-phenotype relationship in LS carriers 
has collectively compared all variations of LS mutations to sporadic control groups 
without mutation status. While this is understandable given the low incidence and 
prevalence of mutation carriers this provided an opportunity in research for this particular 
study. The province of Newfoundland and Labrador presents a unique and valuable 
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population for studying the propagation of autosomal dominant mutations. The island of 
Newfoundland was populated in the late 1700 or early 1800’s by immigrants from either 
the Southwest of England or the Southeast or Ireland with very little migration within the 
island up until recently with modern transportation. The province currently has a 
population of over 500,000 people of which approximately 90% can trace their roots back 
to these original 20-30,000 settlers (Parfrey et al, 2002). The benefit of conducting a 
study of the clinical features of a cancer predisposition syndrome such as Lynch 
Syndrome in a region such as Newfoundland and Labrador (NL) originates from the 
events that led to the colonization of the province. Newfoundland is the most easterly 
Canadian province, and is an island situated in the North Atlantic. The island is 
characterized by the founder effect, large family size and little in or out migration since 
the original founding populations settled in the late 18th and early 19th century (Parfrey et 
al, 2002). 
 
The groundwork for this current study originated from previous investigations of 
large Newfoundland families with autosomal dominant disorders in the province (Parfrey 
et al, 2002). In this particular population of the homogeneity of the environmental 
exposures experienced by the probands, diminishes their potential confounding effects on 
measured clinical outcomes. These previous studies have also been facilitated by 
individuals eager to participate in research, and true population-based health care with 
one tertiary care centre, one provincial medical genetics service and a single tumour 
registry. Almost 50% of all colorectal probands in this province meet the Revised 
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Bethesda and/or Amsterdam II criteria representing the highest rate of familial colorectal 
cancer in the world (Parfrey et al, 2002).  
 
In 1993 a large multi-generational NL family with colorectal and other cancer 
participated in the original study that located a locus on chromosome 2p demonstrating 
the hereditary link this locus and a predisposition to colorectal cancer (Peltomaki, 1993). 
This discovery, subsequently lead to the identification of the germline mutation in the 
MSH2 gene in the 5’ splice site of intron 5 resulting in an in-frame deletion of exon 5 in 
messenger RNA. This MSH2 mutation was subsequently found in 12 other 
Newfoundland families originally from Bonavista North. Initial investigations into the 
genotype-phenotype relationship of this germline mutation identified males as being at 
higher risk of colorectal cancer and death than to female mutation carriers (Green, 2002). 
Continued analysis of other high-risk colorectal and other cancer kindreds lead to the 
discovery of two additional germline mutations in the MSH2 gene in families from 
Newfoundland and Labrador. A genomic deletion in exon 8 was present in these families 
and an exon 4-16 deletion was found in another family. The tumours associated with 
these mutations lack expression of the MSH2 mismatch repair protein that helps regulate 
and correct errors in DNA during replication.  
 
Currently, research has not well described a specific genotype-phenotype 
relationship between all identified germline mismatch repair (MMR) protein mutations 
has not been well described, and whether carriers of different MMR genes have different 
associated cancer risks is unclear. Lynch Syndrome carriers have been shown to be at risk 
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for a spectrum of difference carcinomas however gynecological cancers have been 
identified as being at the top in terms of risk for female probands, above colorectal 
adenocarcinomas. Gynecological cancers have been termed as the sentinel or first-
diagnosed cancer, in a population of carriers that have been diagnosed with both 
colorectal and gynecological (uterine/ovarian) carcinomas (Lu, 2005).  
 
Most recent studies demonstrating the association between Lynch Syndrome 
mutations and EC have combined cohorts of germline mutation-carriers consisting of 
different proportions of carriers of MSH2, MSH6, MLH1, and PMS2 mutations. The 
current study was undertaken in order to determine the genotype-phenotype relationship 
of the three variants of the MSH2 MMR-gene mutations in this province. We sought to 
evaluate the possible effects the specific mutation has on the clinical and pathological 












Chapter 2: Literature Review 
2.1 Background 
The uterus is a pear-shaped organ located in the pelvis between the bladder and 
the rectum. The uterus is composed of three layers; the serous layer of the perimetrium 
that covers the outer surface of the organ; the central or middle layer, the myometrium 
which is composed primarily of smooth muscle as well as stromal vascular tissue, and the 
lining of the uterine cavity called the endometrium that is composed of the basalis and 
functionalis layers. The endometrium is the most dynamic layer as it is greatly influenced 
by the fluctuation of hormones that occur in the normal female reproductive or menstrual 
cycle. During periods of abnormal cellular function, secondary to hormonal influence, 
hereditary errors in cellular proteins, or in other pathways of carcinogenesis not yet 
described, can result in abnormal growth of endometrium along with the ability of these 
cells to proliferate uncontrollably (Blausteins, 2011). Uncontrolled division when normal 
cell regulatory inhibition or apoptosis has been evaded can lead to endometrial 
adenocarcinoma. The neoplasm can spread locally within the cavity of the uterus, invade 
through the myometrium, or in some cases metastasize throughout the body of the 
affected individual.  
 
Endometrial adenocarcinoma (EC) is the most common malignancy of the female 
genital tract of the Western World, and is the fourth most common cancer in women 
behind breast, lung and colorectal cancer (Canadian Cancer society, 2017). Based on 
2017 data, an estimated 1 in 36 women will be diagnosed with EC in their lifetime, and 1 
in 156 women will die from the disease. The vast majority of women will be diagnosed 
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between 50 to 80 years of age, with an average age of 65. The incidence of EC will lead 
to approximately 7,300 Canadian women being diagnosed, and 1,150 of these women 
will succumb to the disease annually, based on data for 2017. The incidence of EC is 
gradually increasing in Westernized countries, and in Canada rates have increased 2.6% 
since 2004 which is a similar to the trend highlighted from the United States (Canadian 
Cancer Society, 2017).  
 
Endometrial carcinoma (EC) refers to a number of different cancers that develop 
in the endometrium or epithelial lining of the uterine cavity. From a pathogenic 
viewpoint, there are two clinicopathologic subtypes of EC that are currently recognized 
as alternate pathways of carcinogenesis of disease. Type I or endometrioid EC, and Type 
II or non-endometrioid EC. Type I endometrioid ECs are estrogen-related tumours that 
typically develop in the pre and peri-menopausal period.  These malignancies often 
coexist with or are preceded by atypical endometrial hyperplasia. Atypical endometrial 
hyperplasia is a condition of excessive proliferation or multiplication of the cells in the 
lining of the endometrium and is often a result of exposure to higher than normal levels 
of endogenous estrogen; a precursor for Type I cancers. Factors that result in an increase 
of endogenous estrogen (e.g. obesity, estrogen-replacement therapy, or estrogen-secreting 
tumours) will increase the risk for developing type I tumours, whereas factors that 
decrease the exposure to endogenous sources of estrogen or increase the exposure to 
progesterone (e.g. multiparity and oral contraceptives) can decrease an individuals risk 
(Okuda, 2010). In the Western World approximately 80% of all diagnosed ECs are of 
endometrioid cell type. Endometrioid tumours are on average diagnosed in women 65 
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years of age, of which, approximately 70% are confined to the corpus of the endometrium 
at the time of diagnosis (Creasman, 2006). Endometrioid tumours are reported to have a 
relatively good prognosis, as their progression rate is slow, and their detection rate is 
high; the cardinal symptom being abnormal vaginal bleeding. Type I tumours are 
associated with a 5-year overall-survival rate of 83% (Creasman, 2006). 
 
 Non-endometrioid or Type II tumours are more commonly diagnosed in 
postmenopausal women with an average age of diagnosis of 67 years. The development 
of these tumours, unlike Type I, is not associated with an increased exposure to estrogen. 
Type II tumours will account for approximately 10-20 percent of all ECs (Creasman, 
2006). Type II tumours include all tumours with non-endometrioid cell histology; clear 
cell carcinoma, papillary serous, mucinous, squamous, transitional cell, and 
undifferentiated tumours are considered within the non-endometrioid classification. Type 
II tumours are found to be more aggressive than their Type I counterparts, and as a result 
approximately 50% of non-endometrioid tumours have spread beyond the corpus of the 
uterus at the time of diagnosis. A malignancy that has breached the serosa of the body of 
the uterus is in turn classified as a more advanced stage of disease and with that carries a 
less favorable prognosis. The 5-year survival for cases varies according to cell type; clear 
cell carcinoma and papillary serious having a 5-year survival rate of 62% and 53% 
respectively (Creasman, 2006). 
 
Following the Federation of Gynecology and Obstetrics (FIGO) meeting in 1988, 
it was concluded that all ECs should be surgically staged in order to assess prognosis, and 
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future treatment for patients. Stage of an EC is the variable most closely correlated with 
predicting prognosis, and patient survival. The stage of an EC is classified based on the 
invasiveness of the cancer into the uterus, as well as migration to local and distal sites in 
the body. An early stage of disease is when the malignancy is localized to the corpus or 
cavity of the uterus. This early classification of disease is limited to stages I/II with 
varying degrees advancement including the depth of myometrial invasion as well as the 
presence of cervical involvement (Blausteins, 2011). An advanced stage of endometrial 
cancer is defined by a tumour expanding through the full thickness of the myometrium, 
and exiting the body of the uterus through the exterior epithelial serosal layer into 
surrounding organs, and structures within the pelvic cavity. As the tumour exits the 
uterus into the pelvic cavity the tumour may invade surrounding structures such as the 
fallopian tubes, ovaries (i.e. adnexa), the vagina/parametrium, bladder or bowel and 
potentially metastasize to distal sites of the body through the lymphatic system. The 
progression of the tumour to distal sites results in a diagnosis of an advanced stage of 
disease, and in turn drastically affecting patient prognosis. Although stage is the variable 
most tightly correlated in predicting patient prognosis, there are a number of other 
prognostic variables that exhibit an influence on prognosis among patients with the same 
stage of disease (Blausteins, 2011).  
 
Tumour grade is a variable evaluated by a clinical pathologist in order to assess a 
tumour or neoplasm appearance at the cellular level under light microscopy. Grade is a 
reflection of the level of differentiation or anaplasia of tumour cells. Anaplasia is the 
degree to which cells have dedifferentiated, or the degree in which the morphological and 
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functional characteristics of a mature cell have been lost compared to a native cell in that 
tissue or organ. In other words, grade is an assessment of how specialized or 
differentiated a cell has become in comparison to a cell that has gone through normal 
cellular development in the same tissue or origin. Grade is evaluated by a number of 
criteria that point to the possibility of malignant transformation and is scaled from Grade 
1 to 4 (or G1-G4). Cells have become more undifferentiated while ascending the scale; 
meaning that as you move up the grade scale, cells are becoming visually and 
functionally increasingly different from a normal cell in a given tissue (Blaustein, 2011). 
Tumour cells that appear well organized, have similar structure and function to the 
normal/native cells of the uterus are classified as grade 1 or 2 (well and moderately 
differentiated tumours respectively). Grade 1 and 2 low-grade tumours are 
characteristically much less invasive than tumours with cell types that present on the 
other end of the grade scale. Grades 3 and 4 (poorly differentiated and undifferentiated 
tumours) are considered high-grade tumours. They are comprised of abnormal cells and 
disorganized tissue structure. These tumours are typically more aggressive, and are 
associated with a higher incidence of advanced stage of disease and metastases 
(Lippincott, 2010).  
 
Identification of an individual with a potential EC is usually suspected upon the 
presentation of abnormal vaginal bleeding, most commonly found in postmenopausal 
women. Abnormal vaginal bleeding is the cardinal symptom associated with EC that 
occurs in seventy-five to ninety percent of all cases. Therefore, women who present with 
abnormal vaginal bleeding should proceed to have an outpatient endometrial pipelle 
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biopsy. If the initial biopsy is not successful or sample is inadequate or returns with a 
negative result, a more sensitive test is recommended completed. The most common 
procedure to definitively diagnose an EC carcinoma is a dilation and curettage under 
general anesthesia, and is considered the gold standard. A dilation and curettage is 
performed by initially dilating the cervical os by mechanical means in order to gain 
access to the body of the uterus. If a mechanical dilation fails, Misoprostol may be used 
as an adjunct to help dilate the cervical os.  (Blaustein, 2011). The second step of the 
procedure involves the surgical removal of the lining or contents of the uterus in order for 
pathological review. The histological findings that result from the endometrial pipelle 
biopsy or dilation and curettage will decide whether a referral to a gynecological 
oncologist is necessary and will determine the course of treatment for the individual. 
 
Despite the incidence of EC affecting Westernized countries including the 
Canadian population, there is currently no evidence for screening asymptomatic women 
for this malignancy. The Papanicolaou smear (pap smear) that is currently used to screen 
for atypical pre-cancerous or cancerous cells of the cervix and endocervix, will detect an 
endometrial cancer approximately 50-percent of the time. Women detected with pre-
cancerous or malignant endometrial cells using this method are shown to have deeper 
myometrial invasion, higher tumour grade and more advanced stage of disease; all of 
these characteristics are predictive of poor patient outcomes (Lippincott, 2010). 
Screening for endometrial cancer or its precursor cells is warranted in certain high-risk 
individuals; including postmenopausal women who are taking exogenous estrogens 
without progestins, premenopausal women with anovulatory cycles, and women with a 
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positive family history are classified as higher risk individuals. HNPCC criteria state that 
women who have been diagnosed with a mismatch repair gene mutation or Lynch 
Syndrome should receive regular screening for endometrial cancers and potentially other 
types of cancers. 
 
2.2 Lynch Syndrome  
Colorectal cancer or large bowel cancer were the malignancies originally 
associated with and studied as the primary malignancy associated with families that fell 
in the criteria of HNPCC. As research proliferated in the field, and the body of 
knowledge surrounding HNPCC expanded, there was a realization that these hereditary 
DNA-MMR mutations were linked to not just colorectal cancer. Malignancies within the 
Lynch Syndrome spectrum include cancers of the colon, endometrium, ovary, stomach, 
upper urinary tract, small-bowel, skin and brain. The identification of this array of 
malignancies and subsequent identification of the genes involved in what is known to be 
LS characterize this cancer predisposition syndrome named after Dr. Henry T. Lynch, 
who was one of the first researchers to describe the hereditary cancer syndrome (Lynch, 
2009). 
 
Lynch Syndrome and its associated cancer susceptibilities are diagnosed through 
confirmatory germline analysis of one or more of four DNA-mismatch repair (DNA-
MMR) gene mutations, MLH1 (MutL homolog 1; chromosome 3p21), MSH2 (MutS 
homolog 2; chromosome 2p16), MSH6 (MutS homolog 6; chromosome 2p16), and PMS2 
(postmeiotic segregation 2; chromosome 7p22). Mutations in these genes result in a 
13 
deficient mismatch repair (MMR) protein system in the cells of the body. The MMR 
protein system functions to preserve the structural, and functional integrity of the DNA 
alpha-helix through the correction of insertion/deletion nucleotide mutations that occur 
during DNA-replication. There are two heterodimeric proteins that recognize nucleotide 
mismatches in a functioning MMR system. The MutS-α heterodimeric protein complex is 
formed by the MSH2 and MSH6 proteins, and is involved in the correction of single 
nucleotide mismatches. The MutS-β protein complex is comprised of the MSH2 and 
MSH3 proteins, and is more commonly involved with the recognition of larger 
insertion/deletion loops (Masuda, 2011). The deactivation of a proper functioning MMR 
system results in an increased rate and accumulation of uncorrected mutations in the 
DNA structure. Insertion/deletion mutations typically occur in microsatellites regions that 
are composed of tandem dinucleotide repeats within the DNA that comprise 
approximately 3% of the gross human genome (Baudhuin, 2005). The increased 
frequency of mutations in microsatellite regions results in a structural imbalance in the 
DNA alpha helix resulting in slippage or bowing of DNA structure manifesting as 
microsatellite instability (MSI); a signature characteristic of a proportion of LS-related 
cancers. The increased frequency of mutation as a result of the impeded MMR-system is 
theorized to lead to the alteration of many other nucleotides involved in numerous 
cellular pathways that limit cell growth, regulate cell death, and together accumulate to 
form the driving force behind the carcinogenic process in LS related malignancies. Given 
the different carcinogenic pathway associated with LS related malignancies as compared 
to Type I and Type II sporadic endometrial cancers, it has been of interest to researchers 
to evaluate the clinical phenotype of LS based endometrial cancers to observe differences 
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in that area as well.  
 
Recent population estimated Lynch Syndrome mutation prevalence in the region 
of 1 in 300 to 1 in 500 in the general population. Lynch Syndrome is characterized by an 
autosomal dominant pattern of inheritance, in that offspring of a proband have a fifty 
percent chance of an inheriting an inactivating mutation of mismatch repair (MMR) 
genes. The recognition of Lynch Syndrome families through pedigree and detection 
guidelines is vitally important for the proper care and future screening of family members 
found to have a germline mutation. The identification of these families allows for 
implementation of proven cancer prevention strategies and provides the opportunity for 
further research into LS families.  
 
2.2.1 Age 
Lynch Syndrome was originally categorized by early onset of cancerous tumours 
developing in the proximal end of the colon. Further research in the field of LS led to the 
discovery that extra-colonic regions were also at an associated increased risk of 
developing neoplasms. In a paper published in 2005 by Lu et al, ECs were reported to be 
most often the first or sentinel cancer for women with this cancer susceptibility 
syndrome. Lu observed that of 101 patients that were diagnosed with two primary 
synchronous cancers of gynecological origin (endometrial carcinoma/ovarian cancer) and 
the other a colorectal cancer, that 51% (n=52) of the time these women had been 
diagnosed with EC or ovarian cancer prior to the diagnosis of colorectal cancer. The 
mean age of the probands diagnosed with endometrial/ovarian cancer first was 44 years 
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of age. Conversely, 49% (n=49) of the women diagnosed with colorectal cancer as their 
first cancer with an average age of 40 years of age at diagnosis. This finding by Lu lead 
to the term of sentinel cancer, suggesting that women with suspected LS would present 
with a gynecological cancer prior to the development of colorectal cancer more than half 
of the time. This would indicate that for families with LS or who fall into the 
classification of HNPCC by the Amsterdam II or Revised Bethesda guidelines, a 
gynecologist plays a pivotal role in the care of these patients. Additionally, professionals 
in the field of Obstetrics and Gynecology should be aware of the early onset of 
gynecological cancers among women with this cancer susceptibility syndrome. The 
diagnosis of EC in a woman provides the opportunity to find LS and prevent further 
cancers.  
 
The observation that women presenting at younger ages with EC increase the 
likelihood of carrying a LS mutation has long been recognized. A cohort of women under 
the age of 40 that were diagnosed with EC were analyzed via immunohistochemistry in 
attempts to evaluate their tumour expression for DNA-mismatch repair (DNA-MMR) 
proteins. Each of the patient tumours were evaluated for four protein markers MLH1, 
MSH2, MSH6, and PSM2. In the total 54 tissue blocks that were examined there was loss 
of expression of at least one MMR protein in 9 of 54 cases (16%). The lack of protein 
expression slightly favored the MSH2/MSH6 abnormalities (five of nine) compared with 
loss of MLH1/PMS2 (four of nine). Though this study demonstrates a correlation between 
younger age of diagnosis of EC and lack of MMR protein expression this does not 
qualify as a diagnosis of LS. A continuation of this study evaluating germline mutations 
16 
in DNA-MMR genes associated with LS would have greatly enhanced this study.  
 
The younger age of diagnosis of ECs in LS probands has been utilized to aid in 
determining the prevalence of loss of MMR protein expression in younger populations 
leading to potential LS families. In a study conducted by Lu et al (2007) that compiled a 
cohort of women diagnosed with EC prior to 50 years of age, germline mutation analysis 
was performed in order to evaluate deletions in MLH1, MSH2, and MSH6 genes. Tumour 
studies conducted included immunohistochemistry analysis for expression of MMR 
proteins (MSH2, MSH6, and MLH1), microsatellite instability, and hypermethylation of 
the MHL1 promoter region. The analysis found that of the 100 women involved in the 
study nine (9%) were found to have deleterious mutations in DNA-MMR genes. The 
majority of the nine deleterious mutations were in MSH2 with a total of seven MSH2 
mutations followed by a single mutation each in the MLH1 and the MSH6 gene variants. 
The study also concluded that in addition to younger age of onset of ECs, that Body Mass 
Index (BMI) could also help identify LS probands as they present with lower BMIs. In a 
retrospective research study performed by Shih et al (2011) a pathological review was 
carried out where pathologic data of patients (n=56) diagnosed with EC before or at 40 
years of age in order to perform DNA-MMR immunohistochemistry analysis on the 
endometrial tumours to try to detect presumptive-LS probands. This study also examined 
clinical risk factors as well as outcomes for these patients with EC under the age of 40 
with EC. The researchers identified nine patients (16%) of the 56 with loss of expression 
of MMR proteins via immunohistochemistry. The germline mutation status of the 
individuals involved in this analysis were unknown. Though this does not constitute a 
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diagnosis of LS, this study further emphasizes the link between a dysfunctional MMR 
system and early age of diagnosis of ECs. Similar to other study findings, lower BMI was 
significantly associated with loss of expression of tumour MMR proteins (Lu 2007). 
 
A study conducted by Walsh et al (2010) on a cohort of patients with early-onset 
EC with diagnosis prior to 50 years of age, had tumour sections undergo 
histopathological review via light microscopy. The tumours were, immunostained and 
evaluated for MHL1, MSH2, MSH6, and PSM2 MMR proteins. The tumours were also 
evaluated for hypermethylation of the MLH1 promoter region as well as microsatellite 
instability. Individuals in the cohort were given a diagnosis of presumptive-LS when they 
presented with loss of expression of at least one MMR protein, and tested negative for 
MLH1 hypermethylation. Presumptive-LS was identified in 26 (18%) of the 146 analyzed 
tumours. Family history was assessed in cases where available, and presumptive-LS 
cases were more likely to be associated with a positive family history when compared 
with families meeting the Amsterdam Criteria II (p < 0.05). The authors conclude 
strongly recommending screening for LS MMR mutations in women who present with 
ECs at or prior to 45 years of age.  
 
Although the younger age of diagnosis has been utilized as a possible LS 
identifier in aiding the search for individuals with MMR gene mutations, there currently 
exists no clear-cut diagnostic strategy for identifying LS carriers. A diagnostic strategy 
was the purpose of a study performed by Leenen et al (2012). The prospective study 
evaluated 179 consecutive ECs diagnosed in patients less than 70 years of age. The study 
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examined tumour tissue samples from the patients in the cohort in order to assess MMR 
protein expression, microsatellite instability status, and BRAF-mutations status. The 
tumours that were identified as microsatellite instability high (MSI-H) cancers, and 
showed loss of expression of MLH1 proteins, underwent an additional testing for 
hypermethylation of the MLH1-promoter region. This additional test was conducted in 
order to distinguish if the loss of protein expression was due to a true germline mutations 
at the MLH1 promoter region or if the region was hypermethylated and in turn silenced or 
under-expressed. After the molecular analysis of the 179 consecutive ECs eleven (6.1%) 
patients were diagnosed with presumptive-LS. The average age of the eleven women 
with the presumptive-LS status was 59 years at diagnosis, which did not differ from the 
median age of sporadic MSI-H tumours (p = 0.19) or microsatellite stable (MSS) tumours 
(p = 0.46). All of the eleven women were then referred to the department of clinical 
genetics in order to undergo germline analysis. Ten of the eleven women accepted the 
referral for confirmatory genetic testing. Seven of the ten women sent to clinical genetics 
were found to have germline mutations in a DNA-MMR gene. Mutations in MSH6 DNA-
MMR gene were found in six individuals with an average age of diagnosis of 55 years. 
The single PSM2 mutation carrier was diagnosed at the age of 69 years. This study found 
that seven (4%) of 179 women diagnosed ≤ 70 years of age were found to have germline 
mutations in MMR genes.  
 
 Lynch Syndrome demonstrates variable penetrance and expressivity in those with 
a specific DNA-MMR gene mutation; variation in phenotype is also seen among different 
MMR mutations. In a research study conducted by Pérez-Cabornero et al (2013) the 
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researchers set out to identify clinical variations among the different LS mutations. 
Statistical analysis was conducted on a cohort of 46 individuals from 22 unrelated 
families with deleterious mutations in MSH2, MSH6, or MLH1 DNA-MMR genes. The 
patients with  EC in this study had varying ages of diagnosis depending on which 
mutation individuals carried. Women with MSH2 gene mutations had an average age of 
diagnosis of 48.2 years of age. In one individual carrying a MSH6 DNA-MMR mutation 
the age of onset was delayed to more than a decade later at 60 years of age demonstrating 
variation among mutations. Similarly, in a study conducted by Ramsoekh et al (2009), 
the researchers set out to evaluate the lifetime risk of cancer in carriers of MLH1, MSH2, 
and MSH6. The results uncovered by the researches were that the MSH6 mismatch repair 
gene carriers were diagnosed with EC much later in life, close to 5-10 years in most cases 
when compared to the MLH1 and MSH2 carriers. The later age of diagnosis of EC 
reached significance in carriers with a MSH6 mutation (56 years of age) when compared 
with MSH2 (46 years of age; p=0.001) and MLH1 (51 years of age; p=0.02) mutation 
carriers. The identification of a genotype-phenotype relationship among LS probands is 
an essential consideration when developing a surveillance program as well as when to 
consider prophylactic surgery for patients.  
2.2.2 Histology 
In contrast to the pathologic characteristic of Lynch Syndrome associated 
colorectal cancer, the pathological and clinical features of EC in Lynch Syndrome have 
not been as well described. The ability to identify Lynch Syndrome mutation carriers 
through LS-associated ECs could increase our ability for recognition of probands with a 
LS mutation. This in turn could aid in prevention of subsequent morbidity and mortality 
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in the identified patient as well as their potential offspring.  
 
In a study performed by Broaddus et al (2006), fifty hematoxylin and eosin slides 
from four different hereditary cancer registries of patients formerly diagnosed with EC 
were reviewed. Reports and as well as the pathological blocks were reviewed from each 
of the cases in order to highlight any pathological or clinically relevant molecular 
features present in these ECs. A single gynecological pathologist examined tumour 
histology for International Federation of Gynecology and Obstetrics (FIGO) stage and 
grade, depth of myometrial invasion, lymphovascular invasion, and cervical involvement 
when available. Each of the patient slides that were reviewed had previously confirmed 
mutations in either MLH1 (n=3) or MSH2 (n=47) DNA-mismatch repair (DNA-MMR) 
genes. As a comparison the LS (HNPCC used in paper but met LS diagnosis standards) 
cohort was compared to two different groups with sporadic ECs. The first control group 
consisted of patients younger than 50 years of age, diagnosed with EC and with no 
known mutation or family history of LS. The second group consisted of women of all 
ages with tumours demonstrating microsatellite instability (MSI) secondary to 
hypermethylation and silencing of the MLH1 promoter region resulting in loss of 
expression in the MLH1 mismatch repair (MMR) protein. The cohort compiled of women 
diagnosed prior to the age of 50 was used because research has demonstration that LS 
associated ECs occur at younger average age than their sporadic counterparts, and the 
MLH1 hypermethylated group was chosen in order to have a group with similar protein 
mechanism defect resulting in microsatellite instability secondary to a defective MMR 
protein system. The researchers found that the tumours in the LS cohort included a more 
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variable histological array of non-endometrioid cell types compared to the other two 
sporadic groups. There were a total of seven (14%) non-endometrioid tumours found in 
the LS cohort, and these histologies were found exclusively in patients carrying MSH2 
mutations. The cell type breakdown for the non-endometrioid tumours were clear cell 
carcinoma (n=3), papillary serous with a clear cell component (n=3) and malignant mixed 
müllerian (n=1). The data from this study is suggesting a potential genotype-phenotype 
relationship in which a deleterious mutation in the MSH2 DNA-MMR gene is associated 
with a variable histological spectrum of ECs that could with other distinguishing factors 
aid in the identification of LS-related neoplasms. Non-endometrioid tumours in sporadic 
cases are associated with worse clinical outcomes in relation to survival (Broaddus, 
2006).   
 
The pathological characteristics of LS-related ECs were evaluated in a study 
Carcangui et al (2010) that compared a cohort of mutation proven LS carriers to a cohort 
of age-matched individuals. For every mutation proven LS proband two sporadic ECs 
with no family history of LS were matched for comparison. The researchers found a 
correlation between non-endometrioid histology and LS-associated ECs. Despite the 
younger age of the LS-associated ECs the cohort was found to have a higher frequency of 
non-endometrioid histologies. The LS cohort was composed of 43.5% of non-
endometrioid endometrial carcinomas (neec) compared to the sporadic cohort with 4.3% 
(p=0.001). Of the 10 neec identified, eight individuals were found in individuals that 
carried a MSH2 DNA-MMR gene mutation. The remaining two individuals were found 
in probands with a proven MLH1 mutation. Five clear cell carcinomas, one of the 
22 
papillary serous carcinomas, and the small cell neuroendocrine carcinoma had a small 
component of endometrioid architecture. The mixed pattern cell types were included in 
the non-endometrioid category as long as they composed of greater than 25% non-
endometrioid component, as their prognosis and behavior have been shown to behave 
similar to that of pure neec. Additionally, all the endometrioid endometrial carcinomas in 
the LS cohort were noted to have a higher frequency of higher-grade tumours compared 
to their sporadic counterparts (P=0.0368).  
 
In an attempt to compare the pathological features of EC in patients with loss of 
expression of mismatch repair (MMR) proteins to those with maintained expression 
Grzankowski et al (2012) compiled a cohort of patients diagnosed with EC less than 60 
years of age. Patients with pure sarcomas and without appropriate available tissue were 
not included in the study. 158 patients were identified for inclusion in the study 
population. Immunohistochemistry analysis was performed for MLH1, MSH2, MSH6, 
and PMS2 proteins identifying 31 patients with loss of expression of MMR proteins. The 
remaining 127 patients maintained MMR protein expression. 25.8% of patients identified 
with loss of MMR protein expression were found to have non-endometrioid tumours 
versus 13.4% of patients that maintained expression; this did not reach statistical 
significance. Loss of MMR protein expression was also noted to present without the 
typical characteristics associated with Type I ECs. These cancers presented with higher 
frequencies of Grade III tumours, more advanced stage of disease, and positive lymph 
node metastases.  
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Walsh et al (2008) published a study where they examined a cohort of patients 
under the age of 50, diagnosed with EC who had their tumours analyzed for expression of 
MMR proteins. Loss of expression of these proteins results in a diagnosis of presumptive-
LS; Amsterdam criteria II was applied when family history was available. This study was 
conducted in order to evaluate the prevalence of presumptive-LS in women diagnosed at 
younger age. Similar to other studies the presumptive-LS cohort had a higher frequency 
of Grade III tumours and a more advanced FIGO staging (Grzankowski, 2012).  
 
Research published by Boks et al (2002) noted that the HNPCC cohort in their 
study demonstrated no statistical difference in the frequency of tumour histological cell 
types when compared to a sporadic cohort. The frequency of non-endometrioid tumours 
in the HNPCC cohort (8%) was lower than the sporadic cohort (12%). The inclusion 
criteria for the HNPCC cohort in this study were from families that harbor a germline LS 
mutation or that have met the Amsterdam Criteria II; the study reported none of the 
MMR mutations of individuals in the HNPCC cohort that were germline tested for LS. 
This study did not release information regarding which DNA-MMR genes were included 
in the HNPCC cohort.  
 
2.2.3 Stage 
The stage of EC reflects the progression of disease at the time of diagnosis and is 
the variable most tightly correlated with patient prognosis. Along with other pathological 
characteristics stage is the most important component used in formulating medical and 
surgical treatment for patients diagnosed with this neoplasm. Patients diagnosed with ECs 
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are typically diagnosed early in the progression of the disease due to the identifiable 
cardinal symptom of abnormal vaginal bleeding. Seventy-five to 90% of women 
diagnosed with EC present with this symptom, and 68% of these carcinomas are confined 
within the uterus at the time of diagnosis. Patients identified at this stage of disease would 
be classified as Stage I disease, which is associated with a 96% five-year survival rate. 
Twenty-percent of women are diagnosed with a more advanced stage of disease where 
the cancer has spread to the lymph nodes (stage II), and 8% are diagnosed with distant 
metastases (Stage III/IV) (Blaustein, 2012). Lynch Syndrome clinical characteristics are 
currently being researched in order to assess for possible differences in disease at the time 
of diagnosis compared to sporadic ECs in turn furthering our understanding of the 
aggressiveness of disease and prognosis.  
 
In a study conducted by Broaddus et al (2005) in order to assess the pathologic 
features of Lynch Syndrome related EC, a cohort of women with mutation-proven Lynch 
Syndrome (probands testing positive for a MSH2 or MLH1 mutation) related ECs was 
compared to two other cohorts. The two cohorts consisted of patients with sporadic ECs 
diagnosed before the age of 50 and another of patients of all ages with tumours 
demonstrating microsatellite instability-high (MSI-high) tumours secondary to 
methylation of the MLH1 gene. In LS cohort in the study 78% of the patients were 
diagnosed with Stage I, 10% were diagnosed with Stage II, and 12% were diagnosed with 
either Stage III or IV disease. When compared to the other two cohorts there was no 
statistical difference in the stage of disease.  
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Clinical, molecular, and pathologic variables were evaluated in a study performed 
by Walsh et al (2008) in order to help improve clinicians alertness to the phenotype of LS 
mutation carriers, and to ameliorate their identification. A total of 146 patients met the 
inclusion criteria for the study. The surgical histological sections from these patients were 
immunologically stained, and assessed for expression of mismatch repair (MMR) 
proteins MLH1, MSH2, MSH6, and PMS2. Tumour DNA was also assessed for 
microsatellite instability, and methylation of MHL1 promoter region. Patients were 
classified as Presumptive Lynch Syndrome patients if tumour analysis showed lack of 
expression in one of the MMR proteins, and negative for MLH1 methylation. In the 
cohort of 146 women, 26 (18%) had tumours that did not express for at least one MMR 
protein. The remaining 120 women in the cohort were classified as non-Lynch and 
compared to the Presumptive-LS cases. The study found that the presumptive-LS cases 
showed a statistical trend towards more advanced FIGO stage in comparison to the non-
Lynch cohort (P=0.029).  
 
 
This was a similar result to a study by Grzankowski et al (2012) that examined 
the pathologic features of patients under the age of 60 with EC that demonstrated loss of 
expression of MMR (MLH1, MSH2, MSH6, and PMS2) proteins as verified by a single 
pathologist from archived tissue blocks using immunohistochemical analysis. One 
hundred and fifty-eight patients were identified from a single tumour registry at Queens 
Medical Center, and 31 of these patients were found to have at least the loss of 
expression of one or more MMR proteins. The breakdown of the 31 patients included 10 
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women with the loss of expression of MSH2/MSH6, and 21 women with the loss of both 
MLH1/PSM2 MMR proteins. Methylation of the MLH1 gene was not conducted to 
identify possible sporadic methylation and silencing of the respective gene. The patients 
found to have loss of expression of MMR proteins were then compared to the women 
with tumours that maintained MMR protein expression. Statistical analysis identified that 
the patients that showed loss of MMR expression were more probable to have a more 
advanced stage of EC than those that maintained protein expression (P= 0.0079). The 
tumours with loss of expression were also found to have more unfavorable disease 
characteristics including greater myometrial invasion (P= 0.0019), increased incidence of 
lymph node metastases (P=0.0157), and increased likelihood of lymphovascular invasion 
(P=0.0020). 
 
 Additionally, Garg et al (2009) conducted a study in attempts to define a 
pathological phenotype for patients with presumptive LS. Out of a total of 2000 possible 
hysterectomies performed at the Memorial Sloan Kettering Cancer Center between 1993 
to 2008 a total of 70 patients met the inclusion criteria of this study; a diagnosis of EC 
aged 40 years or younger. Of the 70 women that met the inclusion criteria, 54 had the 
appropriate tumour blocks available for immunohistochemical analysis for MMR protein 
expression. Out of the 54 cases, nine (16%) were identified to have loss of expression of 
at least one MMR protein, slightly favoring the loss of MSH2/MSH6 (fine of nine), 
compared to loss of MLH1/PMS2 (four of nine). The patients with abnormal or loss of 
expression of MMR proteins were compared to the patients with normally expressed 
MMR proteins on numerous clinical variables. The tumours with loss of MMR protein 
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expression were frequently more associated with lymphovascular invasion (P=0.012), 
often presented with more advanced stages of disease (P=0.005), and were noted to be 
more often located in the lower uterine segment.  
 
The clinical phenotype and pathological presentation of EC in Lynch Syndrome 
carriers can vary tremendously. Carcangui et al (2010) an analysis of 23 Lynch syndrome 
carriers (MSH2 n=16, MLH1 n=6, and MLH1/MSH2 n=1) as confirmed by the detection 
of causative germline mismatch repair (MMR) gene mutations, and diagnosed with EC. 
The Lynch Syndrome cohort was analyzed on clinical variables of grade, and 
International Federation of Gynecology and Obstetrics (FIGO) stage, as well as 
histological type, and survival. This study found that the frequency of FIGO stage did not 
differ between the Lynch Syndrome associated EC cohort, and the control cohort. Despite 
not finding a statistical difference in stage between the two cohorts it was worth noting 
that intravascular invasion was identified in 13 (56.5%) of the LS cohort, compared to 9 
(19.5%) of the controls, as in study by Garg et al 2009. 
2.2.4 Survival 
 Prognosis and survival can be difficult to predict with many variety of neoplasms 
including EC. In order to assess prognosis, the oncologist must take into consideration 
numerous characteristics of the neoplasm and base their predictions on previous 
neoplasms with the same clinical and pathological characteristics. The primary 
characteristics involved in the prediction of patient survival are focused around the 
International Obstetrics and Gynecologist Federation (FIGO) Stage and histological 
characteristics of the neoplasms at the time of diagnosis (Blaustein’s, 2011). The 
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prognosis for EC tends to be favourable as most of these carcinomas are endometrioid 
cell type and diagnosed at a relatively early stage. This early diagnosis is usually due to 
the cardinal symptom of irregular vaginal bleeding in postmenopausal patients. Lynch 
Syndrome related ECs have been identified to deviate from the standard clinical 
phenotype of sporadic varieties, and it has long been recognized that these mutation-
related cancers may be diagnosed decades prior to their sporadic counterparts. 
Researchers are currently evaluating the potential survival differences between Lynch 
Syndrome-related ECs and those found in non-mutation carrying sporadic patients with 
no family history of Lynch Syndrome-related cancers. 
 
The study conducted by Terada et al (2013) evaluated the prognosis, and survival 
of LS-related ECs. This retrospective study compiled a cohort of patients who had been 
diagnosed with LS-related EC between 1998 and 2009 and who had their primary 
tumours evaluated through immunohistochemical analysis for mismatch repair (MMR) 
proteins (MLH1, MSH2, MSH6, and PMS2). Patients in this study that tested negative for 
expression of MLH1 MMR protein were not tested for hypermethylation of this promoter 
region. The inclusion criteria for the study included ECs that tested positive for 
lymphovascular invasion between stages I-IIIA. International Obstetrics and 
Gynecologist Federation (FIGO) stage IIIC-IV were included if lymph node metastases 
were present on biopsy. An upper age boundary of 70 years of age was used so as to 
exclude older patients with increased medical co-morbidities, and to remove these 
variables, and their possible influence on overall survival. Sixty-six patients were 
identified, and met the inclusion criteria. Forty of the inclusion patients were found to 
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have normal expression of MMR proteins in tumour tissue. Negative or under expression 
MMR protein status was defined as tumours stained with respective proteins with less 
than 5% of tumours cells staining positive. Twenty-six of the patients were found to have 
deficient expression of MMR proteins in their tumours; 4 were found to have loss of 
expression of MSH6 and MSH2 proteins, the other 22 were found to have deficient 
expression in either MLH1 or PSM2 protein. Kaplan Meier, and log-rank analysis was 
performed in order to statistically evaluate survival. The overall survival analysis 
between tumours with maintained MMR protein expression, and the cohort that did not 
maintain MMR protein expression were statistically significant (P=0.03). Patients that 
showed deficient expression in MMR proteins were found to have better survival than the 
patients that maintained normal MMR protein expression. A subgroup Kaplan Meier 
survival-analysis was performed including the patients in each group with an FIGO stage 
IIIC cancer. This analysis showed the same trend in that the patient with deficient 
expression had better overall survival (P=0.01). Due to the poor prognostic association 
with FIGO stage IV cancers, an additional subgroup analysis was performed with these 
cancers removed from each of the cohorts. The same statistical significance was found 
with the overall survival of the patients with deficient MMR protein expression (P=0.05), 
although better disease specific survival was not found (P=0.08). 
 
 A survival analysis of fifty patients accumulated from 46 HNPCC families that 
were identified as harboring a germline mutation or fulfilling the Amsterdam Criteria II 
were compared to a cohort of individuals with EC with no outstanding history of HNPCC 
related cancers. In this study initiated by Boks et al (2002) the fifty patients that were in 
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the HNPCC cohort were age, and stage-matched with two sporadic ECs that acted as 
controls. Germline analysis of the HNPCC cohort was confirmed in 38 of the 50 cases 
that comprised the HNPCC group. Sixteen patients were identified to carry a MSH2 
mismatch repair (MMR) gene mutation, three were found to carry a MSH6 MMR gene 
mutation, and 19 were confirmed in carrying a MLH1 MMR gene mutation. The germline 
mutation status in the remaining 12 patients was unknown. Survival analysis was 
complete, and observation time of the analysis was from the date of diagnosis until death 
or until the end of the study date. Survival analysis was complete using log-rank analysis. 
Student t-test was conducted in order to compare the case to the control cohort. The only 
significant difference found between the two groups was the age of the patients with 
Stage IIIA and IIIC ECs. The HNPCC cohort had an average age of diagnosis of 48.0 
years, and the sporadic cohort had an average age of diagnosis of 59.0 years of age 
(P=0.009). The cohorts did not vary significantly in any other baseline characteristics. 
The log-rank analysis demonstrated that the survival between the HNPCC related ECs, 
and the age and stage matched sporadic controls were not significantly different. The 
overall cumulative survival rates for the HNPCC and sporadic cohorts were 88% and 
82% respectively (P=0.59). Subgroup analysis of stage I (A, B, and C) ECs between LS, 
and sporadic cohorts resulted in survival rates of 92%, and 91% respectively (P=0.90). 
Another subgroup analysis of Stages IIIA and IIIC showed no significance difference 
between the two cohorts (P=0.35).  
 
 Lynch Syndrome related EC survival and behavior is not well described in the 
literature. In a study by Carcangui et al (2010) a cohort of 23 patients with Lynch 
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Syndrome related ECs were compared to sporadic EC patients with no personal history of 
Lynch Syndrome associated cancers. The 23 probands in the Lynch Syndrome cohort had 
previously received a germline mutation analysis for at least one mutation of DNA-
mismatch repair (DNA-MMR) gene. The case cohort of 23 consisted of 16 MSH2, 6 
MHL1, and one carrier with both MLH1/MSH2 mutations. The study compared the LS 
cohort to a cohort of sporadic EC patients. Two aged matched controls with no family 
history of LS-related cancers were compared to each Lynch Syndrome proband. The 
study found a significant difference in histology between the two groups, noting that the 
Lynch Syndrome cohort had an increased frequency of non-endometrioid cell types. The 
study then compared the patients in the LS cohort with endometrioid ECs to those with 
non-endometrioid ECs using log-rank analysis that showed that histology did not affect 
overall survival. Despite not affecting the overall survival, the hazard ratio, though not 
statistically significant, was higher (HR=4.86 [0.054-437]; P=0.1583) for the non-
endometrioid patients. 
The overall effect of a non-functional MMR protein system on survival of 
probands is an area of interest for the study conducted by Shikama et al. Consecutive ECs 
(n=221) were analyzed via immunohistochemistry for MMR proteins. Based on the 
findings of the immunohistochemical analysis the patients were categorized as either 
sporadic or Probable Lynch Syndrome (PLS). Probable LS was classified as tumour that 
maintained all MMR proteins (MLH1, MSH2, MSH6, and PMS2) or was found to have 
MLH1 loss of MMR proteins with hypermethylation at the MHL1 promoter region. 
Patients with tumours that demonstrated loss of expression of MSH2, MSH6, or PMS2 
MMR proteins were considered PLS. Patients were also considered PLS if tumours 
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showed loss of expression of MLH1 proteins without methylation at the MLH1 promoter 
region. There were 28 (13%) cases that were classified as PLS and the remaining 193 
(87%) were classified as sporadic ECs. Survival analyses revealed that PLS group had 
significantly better overall survival than the sporadic group (p = 0.038). In an additional 
analysis to compared the prognosis of PLS and sporadic cohorts, the study found that the 
favorable overall survival of the PLS cohort continued in demonstrating a stronger 
association in more advanced stages of disease compared to early stages (hazard ratio, 

















Chapter 3: Materials and Methods 
3.1 Design  
The aim of this pilot study is to compare the clinical features and outcomes of EC 
associated with a Lynch Syndrome mutation with sporadic EC that are presumed 
mutation negative cases and representative of the general population. The ultimate goal 
of the study is to construct a phenotype or clinical picture of how these cancers differ 
from non-LS associated cancers, and as well in the pathological setting in order to 
improve the identification of mutation-based cancers. In turn, we hope to improve the 
probability of identifying LS-related cancers at earlier stages. With increased sensitivity 
of identifying these mutation-based cancers comes improved surveillance programs for 
probands as well as immediate family members that are at an inherited increased risk for 
a spectrum of neoplasms given the autosomal dominant inheritance pattern of LS 
mutations.  
 
In order to fulfill the previously described objectives of this study, it was 
necessary to conduct this research project in three integrated steps. Each of the steps is 
described in detail in the following sections, including the necessary ethical approval and 
considerations in order to conduct research in our health district.  
 
3.2 Ethical Considerations 
An application to conduct this research project was initially sent to the Health 
Research Ethics Authority (HREA) of Newfoundland and Labrador. The Health Research 
Ethics Authority Act established this non-profit agency on July 1st 2011 governing all 
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research involving human subjects or their data in the province. The Health Research 
Ethics Board (HREB) then reviewed the submissions of a Notification of Research form, 
General application form, and The Secondary Use of Data/Chart audit form. The project 
was also submitted for Research Proposal Authority Committee (RPAC) approval 
through Eastern Health. This committee (RPAC) was enacted in order to govern the 
research taking place within the district of Eastern Health in order to monitor resource 
allocation, confidentiality of patients/employees, and stewardship of biological samples. 
Eastern Health is the largest of four regional health authorities in Newfoundland and 
Labrador, servicing a population of approximately 300,000. The study received full 
ethical approval that was renewed throughout the duration of the project.  
 
All of the participants in this study have previously consented to participate in a 
study titled “The Impact of Screening on Individuals from HNPCC Families” and 
therefore re-contact was not required. 
 
3.3 Data Abstraction 
3.3.1 History of Lynch Syndrome Cohort 
The cohort of patients involved with this study is a population of forty-six patients 
with genetic ties to the Northeast coast of Newfoundland and Labrador. These patients 
were originally identified through the investigation to find a gene associated with 
HNPCC. In the early 1990’s two probands were identified independently and referred to 
the Provincial Medical Genetics program in the Newfoundland and Labrador due to their 
significant familial cancer histories. These patients were subsequently investigated and an 
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extensive six-generation family history was uncovered discovering a common ancestor 
between these two probands. This large family, named Family C, played an integral part 
in mapping the first gene in the HNPCC family of mutations, the hMSH2 gene locus 
located on chromosome 2p. The mutation identified through Family C was the intron 5 
splice MSH2 mismatch repair mutation; All of the patients in this study were found to be 
confirmed heterozygotes for this pathogenic variant tested positive for this mutation or 
for the MSH2 exon 8 deletion mutation. The patients being studied in this cohort are 
females that have been identified as mutation carriers either by genetic testing or have 
been proven to be an obligate carrier through the retrospective analysis of their family 
pedigree. All of the probands within this study have consented to have all available 
medical information reviewed in order to extract the details of their respective cancers.  
 
All of the patients included in this cohort have been diagnosed with EC in their 
lifetimes, and the vast majority, have had other synchronous or metachronous Lynch 
Syndrome related cancers during their lives.  
 
3.3.2 Abstraction Form 
The data necessary in order to fulfill the aims of this study was extracted from 
patient charts using an abstraction form. The form was constructed in order to organize 
the clinically relevant data of interest, remove any patient identifying information and to 
improve confidentiality for the patients involved in the study.  The categories included on 
the abstraction form are as follows: 
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• Demographic Information 
• Onset of symptoms  
• Site(s) of Cancer 
• Date of Diagnosis 
• Method of Diagnosis 
• Type of Surgical Procedure 
• Pathology Characteristics 
• Treatment Received  
• Other Cancers 
• Date of Death or Last Follow-up  
The abstraction form was constructed by Dr. Lesa Dawson, MD, FRCSC in collaboration 
with the primary investigator Drs. Jane Green and Adam Nichols . 
 
3.3.3 Patient Charts 
The patient charts that were used in this study were accumulated by Dr. Jane 
Green, Professor in the Discipline of Genetics in the Faculty of Medicine at Memorial 
University of Newfoundland and Labrador. These charts were originally compiled 
through the study of HNPCC for associated gene discovery. Dr. Jane Green compiled the 
charts for the previous study by contacting patients directly either by phone or in-person 
in order to obtain consent to access their medical records. In many cases, the medical 
records did not exist and written dialogues of proband histories were taken. The charts 
consisted of copied versions of original medical records and in some cases hand-written 
notes obtained from probands or family members of the probands regarding medical 
information. The primary investigator then revisited each individual chart that was stored 
on behalf of the original study that were kept securely in the Discipline of Genetics in the 
Faculty of Medicine at Memorial University of Newfoundland and Labrador.  
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The primary investigator manually searched through each of the 46 proband 
charts in order to complete an abstraction form for each individual patient. The majority 
of these charts consisted of medical records relating to each individual neoplasm. This 
would include visits prior to the diagnosis, confirmation of diagnosis, surgical and 
potential chemotherapeutic treatment for each neoplasm and pathological validation of 
the type of cancer for each patient.  
 
3.3.4 Data  
The data for this project was abstracted from patient charts, using the abstraction 
form, for a period lasting from January 2012 to July 2012; solely by the primary 
investigator. The necessary information came from numerous locations within the patient 
charts and was based on queries from gynecological oncologists, geneticists, and the 
literature. The sections included the appointments leading up to and following patient 
diagnosis of endometrial cancer, the surgical and pathology reports, if surgery was 
performed, as well as any adjunctive treatments required by patients post-surgery. The 
patient charts were also reviewed in order to identify any neoplasms that had been 
diagnosed either before or after the diagnosis of endometrial cancer. This was completed 
in order to create an individualized cancer history for each patient involved in the study. 
All the data that was collected for each of the 46 individual patients was manually 
abstracted by the primary investigator (Dr. Adam Nichols) over the six-month period.  
 
If at any point during the abstraction of patient data there was any concern or 
ambiguity in the interpretation of the information, the primary investigator would 
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collaborate with Dr. Lesa Dawson on the research team to ensure the validity of the 
findings. Secondary validation was also conducted by referring to Dr. Jane Green, the 
geneticist on the committee, to ensure the accuracy of the information removed from 
patient charts. As the abstraction forms were completed for each patient, the forms were 
stored in a locked filling cabinet in an office with access limited to the members of the 
research team. In order to validate the pathologic data found in the pathology reports a 
staff pathologist was assigned to the committee in order to confirm the pathological 
diagnoses when possible. Pathological review was achieved by retrieving patient 
histology slides from medical storage when they were available. The staff pathologist 
along with the primary investigator then reviewed the slides manually in order to confirm 
concordance and compared their findings to the pathological data that was retrieved from 
the patient charts.  
Once completed, the information was subsequently entered into a database and 
analyzed with IBM Software Package for the Social Sciences (SPSS) version 22. The 
dataset was constructed from July 2012 to September 2012.  
 
3.3.5 The Sporadic Cohort 
The sporadic cohort was comprised of de-identified data acquired from the 
Newfoundland and Labrador Cancer Registry upon written request and subsequent 
approval. The sporadic cohort represents the general population or presumed non-
mutation based ECs. The data file consisted of consecutive patients diagnosed with EC 
from June 2000 to September 2010 within Newfoundland and Labrador who were treated 
at the Dr. H. Bliss Murphy Cancer Center.  
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The file contained 753 women diagnosed over the ten-year period. The dataset 
included variables of date of birth, date and age of diagnosis, histological information, 
stage of cancer as well as information on follow-up and whether or not the patient 
survived their cancer. The dataset did vary in the amount of information available for 
each individual patient, as not all the mentioned categories were complete for all 
individuals. When patient data was missing they were excluded from the respective 
variables analysis. The majority of the information within the file received from the 
Cancer Registry was easily deciphered, except the histological information, which was 
coded as per the International Classification of Disease for Oncology (ICD-O). The 
information had to be translated back into cell-type information using the ICD-O manual 
by the primary investigator. This involved searching through the dataset for each of the 
753 patients and de-coding the cellular histology for each individual that had the 
information available. If the information was not present for an individual the 
information was requested a second time from the Newfoundland and Labrador Cancer 
Registry; if at that point the information was still not available the patient was excluded 
from the study.  
 
3.3.6 Validity of the Data 
The clinical details regarding the pathological specimens from of the Lynch 
Syndrome patients were collected and abstracted using patient charts as reviewed by the 
primary investigator. After the data was extracted from the patient charts an application 
was submitted to obtain patient surgical/pathological slides from the cancer archive. Not 
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all surgical specimens were available as surgical specimens are only kept for limited time 
frames. This was completed in order to have as many of the surgical slides reviewed by a 
staff pathologist (Dr. Shaikh Mortuza) at the Health Sciences Center in order to validate 
the diagnosis that was assigned to the patient.  
 
The proposal to retrieve the histological slides was submitted, and all of the slides 
that were available for the thirty-six LS associated ECs were retrieved, including any 
other slides that may have been archived from other surgeries on the same patient. Of the 
total 46 LS probands, 36 had histological information abstracted from the charts in 
Discipline of Genetics in the Faculty of Medicine at Memorial University of 
Newfoundland and Labrador. Of the 36 probands with histological information 12 patient 
specimens were retrieved from the surgical archive. The 12 patient specimens were 
reviewed by a single staff pathologist (Dr. Shaikh Mortuza) and the primary investigator 
in order to validate the cell types, when available. 
This process involved the primary investigator and a staff pathologist from the 
Health Sciences Center examining each of the surgical slides under light microscopy. 
This involved three different sessions that included teaching about histology and 
pathology related to the endometrium as well as the evaluation of the slides to confirm 






3.4 Statistical Analysis 
3.4.1 Data Analysis Software 
The data analysis software utilized for this project was IBM Software Package for 
the Social Sciences (SPSS) version 22.  
3.4.2 Data Analysis 
The statistical analysis for this project was a comparison of the hMSH2 mutation-
carrying Lynch Syndrome cohort with that of a sporadic cohort without a Lynch 
Syndrome mutation representative of the general population of Newfoundland and 
Labrador. The primary investigator performed the construction of the datasets by 
transferring the information from the abstraction form to a database. This involved the 
manual transcription of abstraction form data into the SPSS Software Package and 
subsequent coding of the datasets in order to aid analysis. This included classifying the 
data into different types of data as well as their respective coding into different groups in 
order to conduct the appropriate analyses. After the completion of both the datasets for 
the two cohorts, the datasets were merged in order to conduct analytical comparisons 
between all collected variables. The variables that were compared between the two 
cohorts included: 
 
1. Age of diagnosis 
2. Stage of Endometrial Carcinoma (Local versus Advanced)   
3. Cell type  
4. Grade  
5. Overall Survival.  
Comparisons of stage, grade and cell type were all conducted using Chi-Squared 
analysis. The comparison of age was conducted using the Student’s t-test and the survival 
comparison was performed using a Kaplan-Meier Survival Analysis.  
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Chapter 4: Results 
The Lynch Syndrome cohort in this study was compiled of 46 women retrieved 
from the patient charts compiled by Dr. Jane Green, Professor in the Discipline of 
Genetics in the Faculty of Medicine at Memorial University of Newfoundland and 
Labrador from January 2012 to July 2012. The LS cohort consisted of probands with a 
confirmed hMSH2 mutation that had been diagnosed with EC; there were a total of 46 
probands that met these criteria. The information was retrieved from replica photocopies 
of patient charts that were originally collected for research in the HNPCC screening 
program in Newfoundland and Labrador. The secondary use of this data was initiated in 
order to abstract pathological and surgical data that was clinically relevant to the disease 
and progression in the patients who had been previously diagnosed with EC. This 
retrospective analysis was conducted in order to evaluate similarities or differences 
among LS-related ECs and sporadic ECs representative of the general population.  
 
The data that was collected from these charts was additionally cross-referenced 
when possible to the data that was present in the Newfoundland and Labrador Cancer 
Registry on the patients that were diagnosed in this province. This was completed in 
order to ensure that patients that were included in the LS cohort were not concomitantly 
included in the sporadic cohort. This was completed by physically bringing patient charts 
to the Newfoundland and Labrador Cancer Registry to ensure that the Medical Care Plan 
(MCP) numbers did not match. This additional process had to occur as the data sets were 
created in order to maintain the highest level of security and all probands were de-
identified. The comparative data for the sporadic cohort came from the Newfoundland 
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and Labrador Cancer registry from 2000 to 2012. The cases represented consecutively 
enrolled patients that were treated at the Dr. H Bliss Murphy Cancer Center. The data 
from the cancer center were incomplete in that not all patients had data for each of the 
examined variables. When cases from the cancer center had absent data of a particular 
variable they were excluded from the respective analysis. At the end of the data 
collection period the Lynch Syndrome cohort had total of 43 individuals, and the sporadic 


































Table 1: Baseline Demographics and Clinical Characteristics 
 
                          MSH2           Sporadic  
                           n 46(%)           n 753(%) 
Year of Birth       
         1910-1950                         29 (63.0)          511 (67.9) 
         After 1950                         17 (37.0)          242 (32.1) 
        
Age       
Median (Range in Years)                         45 (32-65)          60  (29-92) 
        
Histology       
FIGO Grade 1                          14 (37.8)          325 (60.4) 
FIGO Grade 2                          11 (29.7)          149 (27.7) 
FIGO Grade 3                          12 (32.5)          64 (11.9) 
        
Cell Type       
Endometrioid                        22 (57.9)          532 (70.7) 
Papillary Serous                          9 (23.7)          27 (3.6) 
Clear Cell Carcinoma                          3 (7.9)          6 (0.8) 
Sarcomas                          3 (7.9)          43 (5.7) 
        
FIGO Stage       
Localized (Stages I & II)                        30 (76.9)          340 (88.1) 
Advanced (Stages III & IV)                          9 (23.1)          46 (11.9) 
 
      
       
MSH2 mutation       
Intron 5 spliced site                        33 (73.9)                n/a 
Exon deletion 8                        11 (26.1)                n/a 
        
Dead (all-cause mortality)       
Yes                        23 (54.8)          150 (24.7) 
No                        19 (45.2)          457 (75.3) 
        
 
      
   










4.1 Age Analysis 
 
The Lynch Syndrome cohort and the sporadic cohort were compared in order to 
analyzed the average and median age of diagnosis with Endometrial EC. There were 44 
and 753 in the Lynch Syndrome and Sporadic cohorts respectively that had information 
on age of diagnosis. The analysis was executed using the Student’s t-distribution test in 
order to compare the means of the two cohorts. Levene’s test for equal variances had a p-
value of < 0.05 indicating that the variances for the populations were significantly 
different however it did not change the outcome data. The Student’s t-test distribution 
between the two cohorts differed significantly (p=<0.001). This indicated that the LS-
related ECs are diagnosed at a considerably younger average than the sporadic ECs. The 
mean for the LS cohort was 46.32 years of age (SD- 8.733), with a median age of 45.5. 
The sporadic cohort had an average age of diagnosis of 60.91 years of age (SD- 11.877), 
and a median age of diagnosis of 60.0. The median age for the LS and Sporadic cohorts 







Table 2: Mean age of Diagnosis of EC in Lynch Syndrome and 
Sporadic Cohorts  
Mutation Status Mean N Std. Deviation 
Sporadic Cohort 60.9 753 11.9 
Lynch Syndrome 46.3 44 8.7 
    
46 
 
The Lynch Syndrome and sporadic cohorts were evaluated on age of diagnosis 
before or after fifty-five years of age. The Chi-squared analysis resulted in a Pearson Chi-
squared value of 45.787 with an asymptotic significance value of p < 0.001. The Phi 
coefficient is -0.240. 
 
Table 3: LS/Sporadic comparison of EC diagnosis ≤55 years of Age or > 
  ≤55 >55 	 	Mutation Status No Count  253 500  753 
Expected Count  274.0 479.0  753.0 
 
Yes Count  37 7  44 
Expected Count  16.0 28.0  44.0 
Total Count  290 507  797 
Expected Count  290.0 507.0  797.0 
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4.2 FIGO Grade Analysis 
The analysis of the cohorts was designed in order to identify possible differences 
between the levels of differentiation or grade in ECs within the Lynch Syndrome cohort, 
and those patients in the sporadic cohort. A chi-squared analysis was conducted on the 
LS-related and Sporadic cohorts ECs in order to evaluate for differences in the two 
groups. The cohorts were analyzed independently based on the level of grade. There were 
37 patients in the LS cohort that had information abstracted from their medical history on 
grade of cancer, and 538 total women from the Sporadic cohort that had information on 
grade taken from the Newfoundland and Labrador Cancer Registry. 
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Table 4: FIGO Grade Comparison  
 
Phenotype Lynch Syndrome Sporadic Cohort P-value 
Grade 1 37.8% (14/37) 60.4% (325/538) 0.018* 
Grade 2 29.7% (11/37) 27.7% (149/538) 0.711 
Grade 3 32.4% (12/37) 11.9% (64/538) 0.015* 
 
 
The chi-squared analysis of the Grade 1 or well-differentiated ECs resulted in a 
Pearson chi-squared statistic of 6.463 (p=0.018) indicating a significant difference 
between LS-related ECs and the sporadic cohorts. The Chi-Squared analysis of Grade 2 
or moderately differentiated ECs between the cohorts had a Pearson Chi-Squared statistic 
of 0.137 (p=0.711) indicating no significant difference between the two cohorts. The 
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Pearson Chi-Squared analysis on the Grade 3 or poorly differentiated ECs showed a 
significant association between LS-related ECs and the outcome of developing a poorly 
differentiated tumour. The analysis resulted in a Pearson Chi-Squared value of 10.343 
(p=0.001). 
 The Fisher’s exact test comparing cell grades 1 and 2 combined versus 3 in the 
Lynch Syndrome and sporadic cohort yielded an exact significance of p=<0.001.  
Table 5: Comparison of FIGO Grade 1/2 versus 3 Tumours in LS/Sporadic cohorts 
 Grade 1 /2 Grade 3 Total 
Mutation Status No Count 474 64 538 
Expected Count 466.9 71.1 538.0 
Yes Count 25 12 37 
Expected Count 32.1 4.9 37.0 
Total Count 499 76 575 




4.3 Cell Type Analysis 
The cohorts were compared using Pearson Chi-Squared analysis. The Chi-
Squared analysis did not reach significance (p=0.094) indicating that there is no 
difference between mutation-status and developing either an eec or neec tumour.  
 
The cell types were then broken down into individual sub-classifications of neec 
cell types in order to compare the sub-classes to analyze whether or not LS-related ECs 
had any predominant cell types compared to sporadic ECs. The neec sub-classes included 
sarcomas, clear cell carcinomas, and papillary serous cell types. The incidences of 
sarcoma cell types were compared for association to mutation status. The Pearson Chi-
Squared value from the analysis yielded a result of non-significance (p= 0.547) indicating 
that LS-related ECs did not reach a clinically significant difference of frequency of 
endometrial adenosarcoma compared to the sporadic cohort in this study. 
The prevalence of clear cell carcinomas in the LS cohort compared to the sporadic 
cohort resulting in a statistically significant Pearson Chi-Squared value of 16.202 
(p=<0.001). This demonstrated the frequency of clear cell carcinomas in LS-related ECs 
were more common than in sporadic ECs. 
The Pearson Chi-Squared analysis conducted to compare the frequency of 
papillary serous cell types between the LS and sporadic cohorts resulted in a statistically 








Table 6: Cell Type Comparison 
 
Phenotype Lynch Syndrome Sporadic Cohort P-Value 
Endometrioid 59.4%(22/37) 70.7% (532/753) 0.094 
Papillary Serous 24.3%(9/37)  3.6% (27/ 753) 0.045* 
Clear Cell Carcinoma 8.1% (3/37) 0.8% (6/753) <0.011* 
Sarcoma 8.1% (3/37) 5.7% (43/753) 0.547 
 
 Fisher’s exact test comparison of grouped cell types (papillary serous and clear 
cell carcinoma) versus all other cell types (endometrioid and sarcomas) between the LS 







Table 7: Papillary Serous/ Clear Cell Carcinoma versus other 
cell types comparison between LS and Sporadic cohorts 
 
Non-






No Count 575 33 608 
Expected Count 565.6 42.4 608.0 
Yes Count 25 12 37 
Expected Count 34.4 2.6 37.0 
Total 
  
Count 600 45 645 





4.4 FIGO Stage Analysis 
 
 The Lynch Syndrome cohort had 39 and the sporadic cohort had 387 patients that 
had appropriate data on stage of EC in order to conduct the analysis. Chi-Squared 
analysis was completed comparing local stages of disease (stages I/II) to advanced stages 
of disease (stages III/IV) between the cohorts. The analysis yielded a Pearson Chi-
Squared statistic of 3.916 (p=0.048) demonstrating a significant association between 





Table 8: Comparison of Local and Advanced stage disease 
between LS and Sporadic Cohort  
 
   Local Advanced Total Mutation Status No Count 340 46 386 
Expected Count 336.0 50.0 386.0 
Yes Count 30 9 39 
Expected Count 34.0 5.0 39.0 
Total Count 370 55 425 
Expected Count 370.0 55.0 425.0 
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4.5 Survival Analysis  
The overall lifetime survival of the Lynch Syndrome, and sporadic cohorts were 
compared using the Kaplan-Meier Survival analysis. The Lynch Syndrome cohort had 42 
individuals with information on date of death or last follow-up, and the sporadic cohort 
had 616 patients that had information on date of death or last follow up. The overall 
examination of survival is analyzed using all-cause mortality for these patients after the 
diagnosis of their ECs. The Kaplan-Meier analysis demonstrated no statistical difference 
between the cohorts survival (p=0.068). Though the Lynch Syndrome cohort did 
demonstrate a trend of survival long after their initial diagnosis.  
 
Table 9: Survival Analysis 
  
 
Chi-Square df Sig. 
Log Rank (Mantel-Cox)  3.323 1 0.068 
 
Figure 6: Survival after diagnosis of EC in LS and sporadic cohorts 
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4.6 Predictability Models 
 
 Logistic regression including age of diagnosis of EC before or after the age of 
fifty-five, local versus advanced stage of EC, grade of tumour one and two versus three, 
and grouped cell types of papillary serous and clear cell carcinoma versus all other cell 
types resulted in a Hosmer and Lemeshow Chi-square statistic of 3.062 and p= 0.382. 
Age of diagnosis of EC before or after fifty-five years of age and grouped cell type of 
papillary serous and clear cell carcinoma were both significant predictors in the 
regression equation p= <0.001 and <0.001 respectively.  
 
Table 10: Logistic Regression Predicting Lynch Syndrome 
  B S.E. Wald df Sig. Exp(B) 
Step 1a Age55 -2.596 0.541 23.033 1 0.000 0.075 
Stage Advanced Vs Local 0.702 0.538 1.703 1 0.192 2.018 
Grade1/2or3 0.791 0.504 2.463 1 0.117 2.205 
Papillary Serous /CCC Dicho 2.278 0.593 14.745 1 0.000 9.753 
Constant -2.268 0.668 11.544 1 0.001 0.103 
 
 Multivariate analysis including age of diagnosis of EC before or after the age of 
fifty-five, local versus advanced stage of EC, grade of tumour one and two versus three, 
and grouped cell type of papillary serous and clear cell carcinoma versus all other cell 
types resulted in a Pillai’s trace value of 0.241 and F-value of 20.668 and significant with  
p=<0.001. All dependent variables in the in the analysis are significance in predicting 








Chapter 5: Discussion 
 
 Lynch Syndrome associated EC have been identified by research studies to 
possess unique clinical features compared to sporadic cancers with a functioning MMR 
system ( Backes 2011, Barrow 2009, Baudhuin 2005, Bear 1987, Boks 2002). The 
findings of the LS-related ECs in our study are consistent with other studies showing a 
younger median age of diagnosis. Our prediction models further exemplified these 
findings indicating that patients being diagnosed with EC under the age of fifty-five 
should be considered for MMR protein analysis. Given the common feature of LS-related 
ECs being diagnosed at a younger age when compared to sporadic non-mutation carrying 
patients, it would lead us to speculate that this result is secondary to the lack of 
expression of mismatch repair (MMR) proteins.  
 
The majority of sporadic ECs diagnosed at a young age are well-differentiated 
(Grade 1) tumours. The pathogenesis of these cancers is related to excess endogenous 
estrogen exposure often secondary to body habitus and excess adipose tissue. These 
neoplasms are often preceded by atypical or complex endometrial hyperplasia and follow 
a benign clinical course with favourable prognostic outcomes (Bouquier 2011, Broaddus 
2006). Earlier studies on LS-related ECs highlighted the increased frequency of 
endometrioid endometrial carcinomas (eec) in these tumours finding the incidence as 
high as 92% of cases (Carcangiu 2010). Later research began to indicate a different 
phenotype or clinical picture with studies showing 14% and 43.4 % of non-endometrioid 
endometrial carcinomas (neec) in LS-related ECs (Baudhuin 2005, Bear 1987). This 
further exemplifies the importance of our data findings. Almost half of the LS-related 
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ECs in our cohort were found to have non-endometrioid, Type II tumours. This in 
combination with a young median age at diagnosis deviates from the phenotype of 
sporadic estrogen driven eec that typically comprise eighty percent of sporadic ECs. Most 
studies demonstrate that neec comprise anywhere from 10 to 20% of sporadic ECs, and 
are typically diagnosed in pre or postmenopausal women with an average age between 65 
and 68 years with no identifiable precursor.  
 
The LS-related tumours in our study were associated with a higher frequency of 
papillary serous, and clear cell carcinoma cell types compared to sporadic cases. In our 
prediction models when these cell types (papillary serous and clear cell carcinoma) were 
grouped and compared to all other cell types these cell types were significant predictors 
of LS-related ECs. The increased in frequency of these cell types in LS-related ECs could 
serve as a “red-flag” for patients presenting with these pathologies to ensure more in-
depth family history analysis and screening with the Amsterdam II and Revised Bethesda 
Guidelines and in turn genetic testing.  
 
Antecedent studies researching FIGO grade have linked LS-related ECs with an 
increased frequency of high-grade tumours when compared to sporadic ECs (Baughuin 
2005, Bear 1987, Carcangiu 2010, Classics in Oncology 1985). Our study showed that 
poorly differentiated tumours were also found in higher frequency in LS-related ECs. 
High-grade ECs are associated with decreased survival and an increased incidence of 
metastases. Given that the LS cohort was shown to have an increased frequency of high-
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grade tumours this would lead us to believe that this would negatively impact proband 
survival and overall prognosis if they behave similarly to non-mutation related ECs.  
 
The International Federation of Gynecology and Obstetrics (FIGO) stage has been 
analyzed by previous studies showing higher frequency of stage III tumours in LS-related 
EC as compared to their control cohorts (Bear 1987, Carcangiu 2010). In our study 
analysis on local and advanced stages of disease (combination of stages I/II and III/IV 
respectively) demonstrated that LS-related ECs were more likely to be diagnosed with a 
more advanced stage of disease. In our prediction models, this was not found to be a 
significant predictor of LS for screening purposes. Given that our analysis identified that 
probands in the LS cohort were more likely to have a more advanced stage of disease 
compared to sporadic variants we hypothesize that this would be attributable to the 
impairment on the MMR protein system and subsequent effects on cellular regulation.  
 
In Canada the average age of diagnosis of an EC is approximately 60 years of age 
(Stats Canada, 2017). The average age of diagnosis of EC in our LS cohort was 45 years 
of age, which is more than a decade earlier when compared to national statistics. Our 
analysis of ECs diagnosed before of after 55 years demonstrated that the majority of LS-
related ECs are diagnosed earlier in life when compared to the general population, 
mutation negative ECs. Though this is well known in LS literature this is important 
knowledge for clinicians to consider when diagnosing EC in women with a younger age 
at diagnosis.  In most women, menopause will occur between the ages of fifty and fifty-
five years of age with an average age of occurrence at approximately 51.5. The cardinal 
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symptom for recognition of EC is postmenopausal or abnormal uterine bleeding, which 
occurs in 90% of patients. Our population of LS-related ECs were on average diagnosed 
prior to the average age of menopause. This in turn could delay the diagnosis of EC as 
changes in menstrual bleeding could be attributed to more benign causes by clinicians. 
Given that the stage of disease at diagnosis in the LS cohort was statistically more 
advanced than in the sporadic (older on average) cohort; this could result in theoretical 
delays in diagnosis allowing the progression of the cancers increasing the likelihood of 
their disease becoming more invasive.  
 
 As previously highlighted by Lu et at the incidence of LS-related ECs as Sentinel 
Cancers was 51% in their cohort. The LS cohort in our study demonstrated this 
previously highlighted trend with 69.6% of the women in this cohort diagnosed with EC 
prior to any other neoplasm. Unlike the study by Lu et al, not all the women in our study 
had a synchronous or metachronous neoplasm. This does further exemplify the 
importance in specialty areas of gynecology and gynecological oncology of being 
vigilant towards identifying possible LS-related ECs and referral of the relevant patients 
to medical genetics for genetic testing Cyr 2012). 
 
The results of research comparing the survival of individuals with LS-related ECs 
and sporadic cases is limited. Research in this area has had mixed results some studies 
showing that LS-related ECs have improved survival and others showing that overall 
survival was unaffected. The inclusion criteria in these studies were vastly different 
making it difficult to draw conclusions from the analyses. This comparison highlights the 
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importance of rigid data collection in the clinical and surgical setting. The limitations of 
previous studies highlight the importance of digital health records. Having a digital 
catalog of patient information is vitally important for future research in terms of 
accessibility and storage. Increased quality and accessibility of patient information for 
research is vital in removing obstacles to the progression of any field of research. 
 
The Kaplan-Meyer survival analysis was conducted using date of death or date of 
last follow-up for censoring purposes for both the LS and sporadic EC cohorts. The 
survival analysis demonstrated that the LS-related ECs had the tendency to live longer 
after diagnosis compared to the sporadic cohort but did not obtain statistical significance 
result. Interestingly, this is in spite of the LS cohort having worse prognostic indicators at 
diagnosis. More studies would need to be conducted to assess the reproducibility of these 
results and subsequent analysis comparing younger sporadic ECs with age matched LS 
ECs as the younger age at diagnosis could be a factor improving survival.  
 
5.1 Study Limitations 
This study was designed as a pilot for a larger study assessing the clinical 
phenotype of Lynch Syndrome related ECs and subsequent effect on survival compared 
to disease without a genetic mutation. One of the more significant limitations was the 
lack of ongoing information available on the Lynch Syndrome cohort. As this was a 
retrospective analysis and the use of information was granted from a previous study, 
future studies should involve a new ethics application allowing access to current proband 
electronic medical files when available. This project has begun thorough review of all 
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Lynch Syndrome cases in Newfoundland and Labrador. This would help with specific 
dates of diagnosis and death as well as cause of death in order to enhance the quality of 
the survival analysis. The data that was gathered from the LS proband charts were limited 
with regards to the information surrounding death including cause and date of death.  
This was similar to the limitations that were found in the sporadic cohort data from The 
Newfoundland and Labrador Cancer Registry. The data from the Newfoundland and 
Labrador Cancer Registry did not contain information pertaining to follow up and 
whether or not patients survived their neoplasms. The conclusions that we can draw from 
our Survival Analysis are limited because of the previous mentioned reasons and further 
research in this area would greatly improve our understanding of how these neoplasms 




In conclusion, the Lynch Syndrome-related ECs in this research study presented 
with a different pathological phenotype and younger age of diagnosis than sporadic 
neoplasms in individuals without mutations. The Lynch Syndrome ECs presented as 
higher-grade neoplasms with cell types known to have more aggressive natural histories 
coupled with increased risk of metastases and poor prognosis. Younger ages of diagnosis 
in combination with aggressive cell types (papillary serous/clear cell carcinoma) were 
both predictive of Lynch Syndrome and both these clinical variables should raise the 
suspicion of clinician when presenting concurrently. The Lynch Syndrome related 
neoplasms were also associated with more advanced stage of disease at diagnosis and 
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though this variable was not predictive of LS should warrant a more thorough family 
history analysis. The overall survival of individuals with Lynch Syndrome related ECs 






















1. Backes, F. J., Hampel, H., Backes, K. A., Vaccarello, L., Lewandowski, G., Bell, J. A., . . 
. Cohn, D. E. (2009). Are prediction models for lynch syndrome valid for probands with 
endometrial cancer? Familial Cancer, 8(4), 483-487. doi:10.1007/s10689-009-9273-5; 
10.1007/s10689-009-9273-5  
2. Backes, F. J., Leon, M. E., Ivanov, I., Suarez, A., Frankel, W. L., Hampel, H., . . . Cohn, 
D. E. (2009). Prospective evaluation of DNA mismatch repair protein expression in 
primary endometrial cancer. Gynecologic Oncology, 114(3), 486-490. 
doi:10.1016/j.ygyno.2009.05.026; 10.1016/j.ygyno.2009.05.026  
3. Backes, F. J., Mitchell, E., Hampel, H., & Cohn, D. E. (2011). Endometrial cancer 
patients and compliance with genetic counseling: Room for improvement. Gynecologic 
Oncology, 123(3), 532-536. doi:10.1016/j.ygyno.2011.09.002; 
10.1016/j.ygyno.2011.09.002  
4. Barrow, E., Robinson, L., Alduaij, W., Shenton, A., Clancy, T., Lalloo, F., . . . Evans, D. 
G. (2009). Cumulative lifetime incidence of extracolonic cancers in lynch syndrome: A 
report of 121 families with proven mutations. Clinical Genetics, 75(2), 141-149. 
doi:10.1111/j.1399-0004.2008.01125.x; 10.1111/j.1399-0004.2008.01125.x  
5. Baudhuin, L. M., Burgart, L. J., Leontovich, O., & Thibodeau, S. N. (2005). Use of 
microsatellite instability and immunohistochemistry testing for the identification of 
individuals at risk for lynch syndrome. Familial Cancer, 4(3), 255-265. 
doi:10.1007/s10689-004-1447-6  
63 
6. Bear, J. C., Nemec, T. F., Kennedy, J. C., Marshall, W. H., Power, A. A., Kolonel, V. M., 
& Burke, G. B. (1987). Persistent genetic isolation in outport newfoundland. American 
Journal of Medical Genetics, 27(4), 807-830. doi:10.1002/ajmg.1320270410  
7. Boks, D. E., Trujillo, A. P., Voogd, A. C., Morreau, H., Kenter, G. G., & Vasen, H. F. 
(2002). Survival analysis of endometrial carcinoma associated with hereditary 
nonpolyposis colorectal cancer. International Journal of Cancer.Journal International 
Du Cancer, 102(2), 198-200. doi:10.1002/ijc.10667  
8. Bouquier, J., Blons, H., Narjoz, C., Lecuru, F., Laurent-Puig, P., & Bats, A. S. (2011). 
Microsatellite instability analysis in uterine cavity washings as a screening tool for 
endometrial cancer in lynch syndrome. Familial Cancer, 10(4), 655-657. 
doi:10.1007/s10689-011-9470-x; 10.1007/s10689-011-9470-x  
9. Broaddus, R. R., Lynch, H. T., Chen, L. M., Daniels, M. S., Conrad, P., Munsell, M. F., . 
. . Lu, K. H. (2006). Pathologic features of endometrial carcinoma associated with 
HNPCC: A comparison with sporadic endometrial carcinoma. Cancer, 106(1), 87-94. 
doi:10.1002/cncr.21560  
10. Carcangiu, M. L., Radice, P., Casalini, P., Bertario, L., Merola, M., & Sala, P. (2010). 
Lynch syndrome--related endometrial carcinomas show a high frequency of 
nonendometrioid types and of high FIGO grade endometrioid types. International 
Journal of Surgical Pathology, 18(1), 21-26. doi:10.1177/1066896909332117  
11. Classics in oncology. heredity with reference to carcinoma as shown by the study of the 
cases examined in the pathological laboratory of the university of michigan, 1895-1913. 
by aldred scott warthin. 1913. (1985). CA: A Cancer Journal for Clinicians, 35(6), 348-
359.  
64 
12. Cyr, J. L., Brown, G. D., Stroop, J., & Heinen, C. D. (2012). The predicted truncation 
from a cancer-associated variant of the MSH2 initiation codon alters activity of the 
MSH2-MSH6 mismatch repair complex. Molecular Carcinogenesis, 51(8), 647-658. 
doi:10.1002/mc.20838; 10.1002/mc.20838  
13. Garg, K., Leitao, M. M.,Jr, Kauff, N. D., Hansen, J., Kosarin, K., Shia, J., & Soslow, R. 
A. (2009). Selection of endometrial carcinomas for DNA mismatch repair protein 
immunohistochemistry using patient age and tumour morphology enhances detection of 
mismatch repair abnormalities. The American Journal of Surgical Pathology, 33(6), 925-
933. doi:10.1097/PAS.0b013e318197a046; 10.1097/PAS.0b013e318197a046  
14. Garg, K., & Soslow, R. A. (2014). Endometrial carcinoma in women aged 40 years and 
younger. Archives of Pathology & Laboratory Medicine, 138(3), 335-342. 
doi:10.5858/arpa.2012-0654-RA; 10.5858/arpa.2012-0654-RA  
15. Green, J., O'Driscoll, M., Barnes, A., Maher, E. R., Bridge, P., Shields, K., & Parfrey, P. 
S. (2002). Impact of gender and parent of origin on the phenotypic expression of 
hereditary nonpolyposis colorectal cancer in a large newfoundland kindred with a 
common MSH2 mutation. Diseases of the Colon and Rectum, 45(9), 1223-1232. 
doi:10.1097/01.DCR.0000027034.98952.85 [doi]  
16. Grzankowski, K. S., Shimizu, D. M., Kimata, C., Black, M., & Terada, K. Y. (2012). 
Clinical and pathologic features of young endometrial cancer patients with loss of 
mismatch repair expression. Gynecologic Oncology, 126(3), 408-412. 
doi:10.1016/j.ygyno.2012.05.019; 10.1016/j.ygyno.2012.05.019  
17. Hampel, H., Frankel, W., Panescu, J., Lockman, J., Sotamaa, K., Fix, D., . . . de la 
Chapelle, A. (2006). Screening for lynch syndrome (hereditary nonpolyposis colorectal 
65 
cancer) among endometrial cancer patients. Cancer Research, 66(15), 7810-7817. 
doi:10.1158/0008-5472.CAN-06-1114  
18. Karamurzin, Y., Soslow, R. A., & Garg, K. (2013). Histologic evaluation of prophylactic 
hysterectomy and oophorectomy in lynch syndrome. The American Journal of Surgical 
Pathology, doi:10.1097/PAS.0b013e3182796e27  
19. Koornstra, J. J., Mourits, M. J., Sijmons, R. H., Leliveld, A. M., Hollema, H., & 
Kleibeuker, J. H. (2009). Management of extracolonic tumours in patients with lynch 
syndrome. The Lancet Oncology, 10(4), 400-408. doi:10.1016/S1470-2045(09)70041-5; 
10.1016/S1470-2045(09)70041-5  
20. Kravochuck, S. E., Kalady, M. F., Burke, C. A., Heald, B., & Church, J. M. (2014). 
Defining HNPCC and lynch syndrome: What's in a name? Gut, 63(9), 1525-1526. 
doi:10.1136/gutjnl-2014-307344 [doi]  
21. Leenen, C. H., van Lier, M. G., van Doorn, H. C., van Leerdam, M. E., Kooi, S. G., de 
Waard, J., . . . Steyerberg, E. W. (2012). Prospective evaluation of molecular screening 
for lynch syndrome in patients with endometrial cancer </= 70 years. Gynecologic 
Oncology, 125(2), 414-420. doi:10.1016/j.ygyno.2012.01.049; 
10.1016/j.ygyno.2012.01.049  
22. Ligtenberg, M. J., Kuiper, R. P., Chan, T. L., Goossens, M., Hebeda, K. M., Voorendt, 
M., . . . Hoogerbrugge, N. (2009). Heritable somatic methylation and inactivation of 
MSH2 in families with lynch syndrome due to deletion of the 3' exons of TACSTD1. 
Nature Genetics, 41(1), 112-117. doi:10.1038/ng.283; 10.1038/ng.283  
66 
23. Liu, B., Parsons, R. E., Hamilton, S. R., Petersen, G. M., Lynch, H. T., Watson, P., . . . de 
la Chapelle, A. (1994). hMSH2 mutations in hereditary nonpolyposis colorectal cancer 
kindreds. Cancer Research, 54(17), 4590-4594.  
24. Lynch, H. T., Lynch, P. M., Lanspa, S. J., Snyder, C. L., Lynch, J. F., & Boland, C. R. 
(2009). Review of the lynch syndrome: History, molecular genetics, screening, 
differential diagnosis, and medicolegal ramifications. Clinical Genetics, 76(1), 1-18. 
doi:10.1111/j.1399-0004.2009.01230.x  
25. Lynch, H. T., Shaw, M. W., Magnuson, C. W., Larsen, A. L., & Krush, A. J. (1966). 
Hereditary factors in cancer. study of two large midwestern kindreds. Archives of Internal 
Medicine, 117(2), 206-212.  
26. Mercado, R. C., Hampel, H., Kastrinos, F., Steyerberg, E., Balmana, J., Stoffel, E., . . . 
Colon Cancer Family Registry. (2012). Performance of PREMM(1,2,6), MMRpredict, 
and MMRpro in detecting lynch syndrome among endometrial cancer cases. Genetics in 
Medicine : Official Journal of the American College of Medical Genetics, 14(7), 670-
680. doi:10.1038/gim.2012.18; 10.1038/gim.2012.18  
27. Nyiraneza, C., Marbaix, E., Smets, M., Galant, C., Sempoux, C., & Dahan, K. (2010). 
High risk for neoplastic transformation of endometriosis in a carrier of lynch syndrome. 
Familial Cancer, 9(3), 383-387. doi:10.1007/s10689-010-9321-1; 10.1007/s10689-010-
9321-1  
28. Peltomaki, P., Aaltonen, L. A., Sistonen, P., Pylkkanen, L., Mecklin, J. P., Jarvinen, H., . 
. . Leach, F. S. (1993). Genetic mapping of a locus predisposing to human colorectal 
cancer. Science (New York, N.Y.), 260(5109), 810-812.  
67 
29. Prat, J., Gallardo, A., Cuatrecasas, M., & Catasus, L. (2007). Endometrial carcinoma: 
Pathology and genetics. Pathology, 39(1), 72-87. doi:10.1080/00313020601136153  
30. Resnick, K., Straughn, J. M.,Jr, Backes, F., Hampel, H., Matthews, K. S., & Cohn, D. E. 
(2009). Lynch syndrome screening strategies among newly diagnosed endometrial cancer 
patients. Obstetrics and Gynecology, 114(3), 530-536. 
doi:10.1097/AOG.0b013e3181b11ecc; 10.1097/AOG.0b013e3181b11ecc  
31. Schmeler, K. M., Lynch, H. T., Chen, L. M., Munsell, M. F., Soliman, P. T., Clark, M. 
B., . . . Lu, K. H. (2006). Prophylactic surgery to reduce the risk of gynecologic cancers 
in the lynch syndrome. The New England Journal of Medicine, 354(3), 261-269. 
doi:10.1056/NEJMoa052627  
32. Senter, L., Clendenning, M., Sotamaa, K., Hampel, H., Green, J., Potter, J. D., . . . de la 
Chapelle, A. (2008). The clinical phenotype of lynch syndrome due to germ-line PMS2 
mutations. Gastroenterology, 135(2), 419-428. doi:10.1053/j.gastro.2008.04.026; 
10.1053/j.gastro.2008.04.026  
33. Shah, S. N., Hile, S. E., & Eckert, K. A. (2010). Defective mismatch repair, microsatellite 
mutation bias, and variability in clinical cancer phenotypes. Cancer Research, 70(2), 
431-435. doi:10.1158/0008-5472.CAN-09-3049; 10.1158/0008-5472.CAN-09-3049  
34. Shih, K. K., Garg, K., Levine, D. A., Kauff, N. D., Abu-Rustum, N. R., Soslow, R. A., & 
Barakat, R. R. (2011). Clinicopathologic significance of DNA mismatch repair protein 
defects and endometrial cancer in women 40years of age and younger. Gynecologic 
Oncology, 123(1), 88-94. doi:10.1016/j.ygyno.2011.06.005; 
10.1016/j.ygyno.2011.06.005  
68 
35. Stoffel, E., Mukherjee, B., Raymond, V. M., Tayob, N., Kastrinos, F., Sparr, J., . . . 
Gruber, S. B. (2009). Calculation of risk of colorectal and endometrial cancer among 
patients with lynch syndrome. Gastroenterology, 137(5), 1621-1627. 
doi:10.1053/j.gastro.2009.07.039; 10.1053/j.gastro.2009.07.039  
36. Stuckless, S., Green, J., Dawson, L., Barrett, B., Woods, M., Dicks, E., & Parfrey, P. 
(2012). Impact of gynecological screening in lynch syndrome carriers with an MSH2 
mutation. Clinical Genetics, doi:10.1111/j.1399-0004.2012.01929.x; 10.1111/j.1399-
0004.2012.01929.x  
37. Stuckless, S., Parfrey, P. S., Woods, M. O., Cox, J., Fitzgerald, G. W., Green, J. S., & 
Green, R. C. (2007). The phenotypic expression of three MSH2 mutations in large 
newfoundland families with lynch syndrome. Familial Cancer, 6(1), 1-12. 
doi:10.1007/s10689-006-0014-8  
38. Vasen, H. F., Watson, P., Mecklin, J. P., Jass, J. R., Green, J. S., Nomizu, T., . . . Lynch, 
H. T. (1994). The epidemiology of endometrial cancer in hereditary nonpolyposis 
colorectal cancer. Anticancer Research, 14(4B), 1675-1678.  
39. Walsh, C. S., Blum, A., Walts, A., Alsabeh, R., Tran, H., Koeffler, H. P., & Karlan, B. Y. 
(2010). Lynch syndrome among gynecologic oncology patients meeting bethesda 
guidelines for screening. Gynecologic Oncology, 116(3), 516-521. 
doi:10.1016/j.ygyno.2009.11.021; 10.1016/j.ygyno.2009.11.021  
40. Walsh, M. D., Cummings, M. C., Buchanan, D. D., Dambacher, W. M., Arnold, S., 
McKeone, D., . . . Obermair, A. (2008). Molecular, pathologic, and clinical features of 
early-onset endometrial cancer: Identifying presumptive lynch syndrome patients. 
Clinical Cancer Research : An Official Journal of the American Association for Cancer 
69 
Research, 14(6), 1692-1700. doi:10.1158/1078-0432.CCR-07-1849; 10.1158/1078-
0432.CCR-07-1849  
41. Woods, M. O., Hyde, A. J., Curtis, F. K., Stuckless, S., Green, J. S., Pollett, A. F., . . . 
Parfrey, P. S. (2005). High frequency of hereditary colorectal cancer in newfoundland 
likely involves novel susceptibility genes. Clinical Cancer Research : An Official Journal 
of the American Association for Cancer Research, 11(19 Pt 1), 6853-6861. 
doi:10.1158/1078-0432.CCR-05-0726  
42. Zauber, N. P., Denehy, T. R., Taylor, R. R., Ongcapin, E. H., Marotta, S. P., Sabbath-
Solitare, M., . . . Bishop, D. T. (2010). Microsatellite instability and DNA methylation of 
endometrial tumours and clinical features in young women compared with older women. 
International Journal of Gynecological Cancer : Official Journal of the International 

























Amsterdam II criteria  
1. Three or more relatives with histologically verified Lynch syndrome-associated 
cancers (CRC, cancer of the endometrium or small bowel, transitional cell 
carcinoma of the ureter or renal pelvis), one of whom is a first-degree relative of 
the other two and in whom familial adenomatous polyposis (FAP) has been 
excluded. 
2. Lynch syndrome-associated cancers involving at least two generations. 
3. One or more cancers were diagnosed before the age of 50 years. 
 
Revised Bethesda Criteria  
1. Colorectal or uterine cancer diagnosed in a patient how is less than 50 years of 
age. 
2. Presence of synchronous, metachronous colorectal, or other HNPCC-associated 
tumours, * regardless of age. 
3. Colorectal cancer with the MSI-H ** histology *** diagnosed in a patient who is 
less than 60 years of age.  
4. Colorectal cancer diagnosed in one or more first-degree relatives with an 
HNPCC-related tumour, with one of the cancers being diagnosed under age 50 
years. 
5. Colorectal cancer diagnosed in two or more first- or second-degree relatives with 
HNPCC-related tumours, regardless of age 
 
Synchronous neoplasias: are defined as 2 or more primary tumours identified in the 
same patient and at the same time. 
 
Metachronous neoplasias: tumours are defined as primary tumours developing 6 
months after the first primary has been resected.  
 
Presumptive-Lynch Syndrome: Patients were conservatively classified as presumptive 
Lynch syndrome if their tumours showed loss of at least one mismatch repair protein and 
were negative for methylation of MLH1 
 
Hypermethylation: is an epigenetic control aberration that is important in gene 
inactivation in the majority of tumour analysis. Hypermethylation of CpG islands have 
been described in almost all tumour analysis. In the context of this research paper it refers 
to gene silencing of Mismatch repair genes.  
	
	
